Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled trial of cannabidiol for preservation of beta-cell function in newly diagnosed type 1 diabetes mellitus
MOH_2019-09-02_007376Phase 2Not yet recruiting
- Sponsor
- BOL Pharma
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing Cannabidiol add-on with Placebo add-on (2 arms). Planned start Jan 2019; status: not yet recruiting.
02
Drugs
cannabidiol
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on MOH_2019-09-02_007376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-09-02_007376.